To evaluate if other antigens might be preferable to BCMA for the detection of myeloma EVs, we evaluated 15 samples from 5 of the 10 patients treated with Belantamab (cycles 1 to 3) and quantified EVs with the following antigens: CD23, CD27, CD38, CD56 and CD138. This evidence concerns the gene CD27 and plasma cell myeloma.